IMMUNOLOGY. For the article “Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans,” by Ian D. Davis, Weisan Chen, Heather Jackson, Phillip Parente, Mark Shackleton, Wendie Hopkins, Qiyuan Chen, Nektaria Dimopoulos, Tina Luke, Roger Murphy, Andrew M. Scott, Eugene Maraskovsky, Grant McArthur, Duncan MacGregor, Sue Sturrock, Tsin Yee Tai, Simon Green, Andrew Cuthbertson, Darryl Maher, Lena Miloradovic, Susan V. Mitchell, Gerd Ritter, Achim A. Jungbluth, Yao-Tseng Chen, Sacha Gnjatic, Eric W. Hoffman, Lloyd J. Old, and Jonathan S. Cebon, which appeared in issue 29, July 20, 2004, of Proc. Natl. Acad. Sci. USA (101, 10697–10702; first published July 13, 2004; 10.1073/pnas.0403572101), the authors note that on page 10701, first column, second full paragraph, “With a median followup of 748 days, 16 have relapsed: five of seven placebo pts, nine of 16 who received protein alone and two of 19 who received NY-ESO-1 with IMX” should read: “With a median followup of 748 days, 16 have relapsed: five of seven placebo pts, six of 16 who received protein alone and two of 19 who received NY-ESO-1 with IMX.” The conclusions of the article remain unchanged.